Clover Health Announces Changes to Board of Directors
Clover Health (Nasdaq: CLOV) announced significant changes to its Board of Directors. Lee A. Shapiro, current Chairman of the Audit Committee and Nominating and Corporate Governance Committee, will not seek re-election at the 2025 Annual Shareholders' Meeting, concluding his four-year tenure on June 10, 2025.
Shapiro's departure is due to his upcoming role as Chairman of the American Heart Association. Thomas L. Tran, a current Audit Committee member, will succeed Shapiro as Chairman of both the Audit Committee and the Nominating and Corporate Governance Committee effective June 10, 2025.
Both CEO Andrew Toy and Executive Chairperson Vivek Garipalli expressed gratitude for Shapiro's contributions and leadership during his tenure, while Tran committed to maintaining high standards of financial integrity and transparency in his new role.
Clover Health (Nasdaq: CLOV) ha annunciato importanti cambiamenti nel suo Consiglio di Amministrazione. Lee A. Shapiro, attuale Presidente del Comitato di Revisione e del Comitato per la Nomina e la Governance Aziendale, non si ricandiderà all'Assemblea Annuale degli Azionisti del 2025, concludendo il suo mandato quadriennale il 10 giugno 2025.
La decisione di Shapiro è legata al suo prossimo ruolo come Presidente dell'American Heart Association. Thomas L. Tran, membro attuale del Comitato di Revisione, succederà a Shapiro come Presidente di entrambi i comitati a partire dal 10 giugno 2025.
Sia il CEO Andrew Toy sia il Presidente Esecutivo Vivek Garipalli hanno espresso gratitudine per il contributo e la leadership di Shapiro durante il suo mandato, mentre Tran si è impegnato a mantenere elevati standard di integrità finanziaria e trasparenza nel suo nuovo incarico.
Clover Health (Nasdaq: CLOV) anunció cambios significativos en su Junta Directiva. Lee A. Shapiro, actual Presidente del Comité de Auditoría y del Comité de Nominaciones y Gobernanza Corporativa, no buscará la reelección en la Asamblea Anual de Accionistas de 2025, concluyendo su mandato de cuatro años el 10 de junio de 2025.
La salida de Shapiro se debe a su próximo rol como Presidente de la American Heart Association. Thomas L. Tran, miembro actual del Comité de Auditoría, sucederá a Shapiro como Presidente de ambos comités a partir del 10 de junio de 2025.
Tanto el CEO Andrew Toy como el Presidente Ejecutivo Vivek Garipalli expresaron su agradecimiento por las contribuciones y el liderazgo de Shapiro durante su mandato, mientras que Tran se comprometió a mantener altos estándares de integridad financiera y transparencia en su nuevo cargo.
Clover Health (나스닥: CLOV)는 이사회의 중대한 변화를 발표했습니다. 현재 감사위원회 및 지명 및 기업 거버넌스 위원회 의장인 Lee A. Shapiro는 2025년 6월 10일에 4년 임기를 마치고 2025년 연례 주주총회에서 재선에 도전하지 않을 예정입니다.
Shapiro의 퇴임은 그가 곧 American Heart Association 의장으로 활동하게 되는 데 따른 것입니다. 현재 감사위원회 위원인 Thomas L. Tran가 2025년 6월 10일부터 두 위원회의 의장직을 이어받을 예정입니다.
CEO Andrew Toy와 집행 의장 Vivek Garipalli는 Shapiro의 임기 동안의 기여와 리더십에 감사를 표했으며, Tran은 새로운 역할에서 높은 재무 투명성과 청렴성을 유지할 것을 약속했습니다.
Clover Health (Nasdaq : CLOV) a annoncé des changements importants au sein de son conseil d'administration. Lee A. Shapiro, actuel président du comité d'audit ainsi que du comité de nomination et de gouvernance d'entreprise, ne sollicitera pas sa réélection lors de l'assemblée générale annuelle des actionnaires de 2025, mettant fin à son mandat de quatre ans le 10 juin 2025.
Le départ de Shapiro est lié à sa prochaine fonction de président de l'American Heart Association. Thomas L. Tran, membre actuel du comité d'audit, succédera à Shapiro en tant que président des deux comités à compter du 10 juin 2025.
Le PDG Andrew Toy et le président exécutif Vivek Garipalli ont tous deux exprimé leur gratitude pour les contributions et le leadership de Shapiro durant son mandat, tandis que Tran s'est engagé à maintenir des normes élevées d'intégrité financière et de transparence dans ses nouvelles fonctions.
Clover Health (Nasdaq: CLOV) gab bedeutende Veränderungen in seinem Vorstand bekannt. Lee A. Shapiro, derzeitiger Vorsitzender des Prüfungsausschusses sowie des Nominierungs- und Corporate-Governance-Ausschusses, wird bei der Hauptversammlung 2025 nicht erneut kandidieren und seine vierjährige Amtszeit am 10. Juni 2025 beenden.
Shapiros Ausscheiden hängt mit seiner bevorstehenden Rolle als Vorsitzender der American Heart Association zusammen. Thomas L. Tran, derzeit Mitglied des Prüfungsausschusses, wird Shapiro ab dem 10. Juni 2025 als Vorsitzender beider Ausschüsse nachfolgen.
Sowohl CEO Andrew Toy als auch der Executive Chairman Vivek Garipalli dankten Shapiro für seinen Beitrag und seine Führung während seiner Amtszeit, während Tran sich verpflichtete, in seiner neuen Rolle hohe Standards in finanzieller Integrität und Transparenz aufrechtzuerhalten.
- Smooth leadership transition planned with experienced board member Thomas L. Tran taking over key committee roles
- Orderly succession process with clear timeline and responsibilities defined
- Loss of experienced board member who provided valuable insights during his tenure
Thomas L. Tran will become Chairman of the Audit Committee and the Nominating and Corporate Governance Committee, and Lee A. Shapiro will not stand for re-election at the 2025 Annual Shareholders’ Meeting
WILMINGTON, Del., April 22, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that after four years of distinguished service, Lee A. Shapiro, a member of Clover Health’s Board of Directors, has notified the Company of his intention not to stand for reelection to the Board of Directors in light of new responsibilities related to his assumption of the Chairmanship of the American Heart Association in the coming weeks. Mr. Shapiro will fulfill the remainder of his term as a member of the Board of Directors, ending his service as of June 10, 2025, the date of the Company’s 2025 Annual Shareholders’ meeting.
“It has been a privilege to serve on the Clover Health Board of Directors for the prior four years,” said Lee A. Shapiro. “I am very proud of what I have been able to contribute in my role on the Board, as well as what the Company has accomplished in that same time span. I wish Clover continued and even greater success in the future.”
“We are grateful for Lee’s dedicated service and leadership on Clover’s Board of Directors,” said Andrew Toy, CEO of Clover Health. “Throughout his tenure on the Board, Lee has provided invaluable insight to advance the Clover mission. We thank him for his contributions and wish him all the best in his future endeavors.”
“Lee Shapiro has been an incredible partner to Clover, bringing a mix of discipline, heart, and experience that’s hard to replicate. His belief in our mission and his leadership on the Board have helped us navigate critical chapters of our journey,” said Vivek Garipalli, Executive Chairperson and founder of Clover Health. “We’re deeply grateful for his service and wish him every success in this next chapter. I’m also thrilled to see Tom Tran step into this expanded role—he brings deep expertise and judgment, and we’re lucky to have him help guide Clover moving forward.”
Mr. Shapiro serves as Chairman of the Audit Committee and the Nominating and Corporate Governance Committee. Effective June 10, 2025, Thomas L. Tran, a current member of the Audit Committee, will be appointed Chairman of the Audit Committee and as a member and Chairman of the Nominating and Corporate Governance Committee.
"I am honored to take on the role of Chairman for both the Audit Committee and the Nominating and Corporate Governance Committee,” said Thomas L. Tran, Clover Health Board Member. “Building upon Lee's strong leadership, I am committed to upholding the highest standards of financial integrity and transparency at Clover. I look forward to continuing to foster an environment of rigorous oversight, accountability, and ensuring that we serve the best interests of our stakeholders."
About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.
Investor Relations:
Ryan Schmidt
investors@cloverhealth.com
Press Inquiries:
press@cloverhealth.com
FAQ
When will Lee Shapiro step down from Clover Health's (CLOV) Board of Directors?
Who will replace Lee Shapiro as Chairman of CLOV's Audit Committee?
Why is Lee Shapiro leaving Clover Health's (CLOV) Board of Directors?
How long did Lee Shapiro serve on CLOV's Board of Directors?
